Last updated: 2026-10-13 21:20:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Becton, Dickinson and Co. (BDX) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NYSE. The stock is currently priced at $187.33, with a market capitalisation of $50.05B and a P/E ratio of 54.68. Over the past 52 weeks, its price has ranged from $140.11 to $213.08. This page covers its latest market performance, valuation, price trends and company information.
$50.05B | |
$189.82 | |
$287.32 | |
$34.10 | |
$188.89 | |
868.77K | |
1.79M | |
54.68 | |
$213.08 | |
$140.11 | |
2.28% | |
-- |
Becton, Dickinson and Co. (BDX) is trading at $187.34 in after-hours trading as of 2026-10-13 20:26:46, down 0.82% ($1.55) from the regular-session close of $188.89.
After-hours trading shows how investors are pricing BDX after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Becton, Dickinson and Co. (BDX) moved from $176.80 to $187.33, representing a gain of 5.96% ($10.53).
The stock traded between $175.71 and $189.82 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 1.69 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 64.7%
BDX is currently trading at $187.33, placing it 64.7% of the way from its 52-week low of $140.11 to its 52-week high of $213.08. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Following the separation of the life science segment, Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 72000 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of Becton, Dickinson and Co. (BDX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.